Evidence map›Paper›PMID 32052252›Full record

ArticleFamilial cancer2020

Novel intronic variant in PALB2 gene and effective prevention of Fanconi anemia in family.

I Viakhireva, E Musatova, L Bessonova, Y Shcherbatyuk, S Korobkov, S Zhikriveckaya, Ya Sofronova, I Mironova, D Khmelkova, F Konovalov and 3 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Familial cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Masks of Albinism: Clinical Spectrum of Hermansky-Pudlak Syndrome.International journal of molecular sciences · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

I ViakhirevaResearch Centre for Medical Genetics, Moskvorechie, 1, Moscow, Russian Federation, 115522.
E MusatovaResearch Centre for Medical Genetics, Moskvorechie, 1, Moscow, Russian Federation, 115522.
L BessonovaResearch Centre for Medical Genetics, Moskvorechie, 1, Moscow, Russian Federation, 115522.
Y ShcherbatyukHospital Lapino, MD Medical Group, 111, 1-Ye Uspenskoye Shosse, Lapino, Moskovskaya region, Russian Federation, 143081.
S KorobkovHospital Lapino, MD Medical Group, 111, 1-Ye Uspenskoye Shosse, Lapino, Moskovskaya region, Russian Federation, 143081.
S ZhikriveckayaCenter of Genetics and Reproductive Medicine "Genetico", LLC, 3 b1, Gubkina str, Moscow, Russian Federation, 119333.
Ya SofronovaCenter of Genetics and Reproductive Medicine "Genetico", LLC, 3 b1, Gubkina str, Moscow, Russian Federation, 119333.
I MironovaCenter of Genetics and Reproductive Medicine "Genetico", LLC, 3 b1, Gubkina str, Moscow, Russian Federation, 119333.
D KhmelkovaGenomed, Ltd, 8 b5, Podol'skoye Shosse, Moscow, Russian Federation, 115093.
F KonovalovGenomed, Ltd, 8 b5, Podol'skoye Shosse, Moscow, Russian Federation, 115093.
A BaranovaResearch Centre for Medical Genetics, Moskvorechie, 1, Moscow, Russian Federation, 115522.
E PomerantsevaCenter of Genetics and Reproductive Medicine "Genetico", LLC, 3 b1, Gubkina str, Moscow, Russian Federation, 119333.
M SkoblovResearch Centre for Medical Genetics, Moskvorechie, 1, Moscow, Russian Federation, 115522. mskoblov@gmail.com.
Research Centre for Medical Genetics · RUGeorge Mason University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the acceptance of NextGen sequencing as a diagnostic modality suitable for probands and carriers of Mendelian diseases, its efficiency in identifying causal mutations is limited by both technical aspects of variant call algorithms and by imperfect, consensus-based criteria for assessing the pathogenicity of the findings. Here we describe the medical history of the family with a child born with Fanconi anemia. In this case, typical diagnostic routines were complicated by unusual combination of mutations. PALB2 variant NM_024675.3:c.172_175delTTGT (p.Gln60Argfs) in maternal sample, previously classified as a definitely pathogenic frameshift mutation, was in compound heterozygous state with PALB2 NM_024675.3:c.3114-16_3114-11del (p.Asn1039Glyfs*7), which led to validated PALB2 exon 11 skipping event in paternal locus. Findings enabled the development of the PGТ and successful selection of two mutation-free embryos. We show that even in absence of definitive exome findings, clinician-guided research inquiries into the structure and function of the suspected loci allow definitive diagnosis. Described case provides an example of a crucial input of an investigational workflow in genetic prognosis and successful PGT.

Indexed as

Frameshift MutationAdultChild, PreschoolExome SequencingExonsFanconi AnemiaFanconi Anemia Complementation Group N ProteinFatal OutcomeFemaleFertilization in VitroGenetic TestingHigh-Throughput Nucleotide SequencingHumansInfantIntronsMaleFanconi Anemia Complementation Group N ProteinPALB2 protein, humanRNA, MessengerFanconi anemiaFunctional analysisMinigene assayPALB2Preimplantation genetic testingSplicing mutations

Identifiers

PMID32052252
OpenAlexW3006260451

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.